Affordable Access

deepdyve-link
Publisher Website

Chronic lymphocytic leukemia and mantle cell lymphoma: crossroads of genetic and microenvironment interactions.

Authors
  • Puente, Xose S1, 2
  • Jares, Pedro2, 3, 4
  • Campo, Elias2, 3, 4
  • 1 Departamento de Bioquímica y Biología Molecular, Instituto Universitario de Oncología, Universidad de Oviedo, Oviedo, Spain. , (Spain)
  • 2 Centro de Investigación Biomédica en Red de Cáncer, Madrid, Spain. , (Spain)
  • 3 Hematopathology Section, Laboratory of Pathology, Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain; and. , (Spain)
  • 4 Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain. , (Spain)
Type
Published Article
Journal
Blood
Publisher
American Society of Hematology
Publication Date
May 24, 2018
Volume
131
Issue
21
Pages
2283–2296
Identifiers
DOI: 10.1182/blood-2017-10-764373
PMID: 29666114
Source
Medline
Language
English
License
Unknown

Abstract

Chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) are 2 well-defined entities that diverge in their basic pathogenic mechanisms and clinical evolution but they share epidemiological characteristics, cells of origin, molecular alterations, and clinical features that differ from other lymphoid neoplasms. CLL and MCL are classically considered indolent and aggressive neoplasms, respectively. However, the clinical evolution of both tumors is very heterogeneous, with subsets of patients having stable disease for a long time whereas others require immediate intervention. Both CLL and MCL include 2 major molecular subtypes that seem to derive from antigen-experienced CD5+ B cells that retain a naive or memory-like epigenetic signature and carry a variable load of immunoglobulin heavy-chain variable region somatic mutations from truly unmutated to highly mutated, respectively. These 2 subtypes of tumors differ in their molecular pathways, genomic alterations, and clinical behavior, being more aggressive in naive-like than memory-like-derived tumors in both CLL and MCL. The pathogenesis of the 2 entities integrates the relevant influence of B-cell receptor signaling, tumor cell microenvironment interactions, genomic alterations, and epigenome modifications that configure the evolution of the tumors and offer new possibilities for therapeutic intervention. This review will focus on the similarities and differences of these 2 tumors based on recent studies that are enhancing the understanding of their pathogenesis and creating solid bases for new management strategies. © 2018 by The American Society of Hematology.

Report this publication

Statistics

Seen <100 times